{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:07:33Z","timestamp":1773788853627,"version":"3.50.1"},"reference-count":22,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v103.5278","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T11:55:30Z","timestamp":1681905330000},"page":"adv5278","source":"Crossref","is-referenced-by-count":10,"title":["Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study"],"prefix":"10.2340","volume":"103","author":[{"given":"Federica","family":"Repetto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Roccuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Burzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"30982","doi-asserted-by":"crossref","unstructured":"Morita A, Takahashi H, Ozawa K, Imafuku S, Takekuni N, Takahashi K, et al. Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: open-label phase 3 results. J Dermatol 2021; 48: 3-13.","DOI":"10.1111\/1346-8138.15605"},{"key":"30983","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.15605","DOI":"10.1111\/1346-8138.15605"},{"key":"30984","doi-asserted-by":"crossref","unstructured":"Roccuzzo G, Rozzo G, Burzi L, Repetto F, Dapavo P, Ribero S, Quaglino P. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: what's beyond cost-effectiveness? Dermatol Ther 2022; 35: e15803.","DOI":"10.1111\/dth.15803"},{"key":"30985","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15803","DOI":"10.1111\/dth.15803"},{"key":"30986","doi-asserted-by":"crossref","unstructured":"Markota \u010cagalj A, Marinovi\u0107 B, Bukvi\u0107 Mokos Z. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci 2022; 23: 3753.","DOI":"10.3390\/ijms23073753"},{"key":"30987","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/ijms23073753","DOI":"10.3390\/ijms23073753"},{"key":"30988","doi-asserted-by":"crossref","unstructured":"Repetto F, Burzi L, Ribero S, Quaglino P, Dapavo P. Efficacy and safety of risankizumab in hidradenitis suppurativa: a case series. Acta Derm Venereol 2022; 102: adv00780.","DOI":"10.2340\/actadv.v102.2926"},{"key":"30989","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/actadv.v102.2926","DOI":"10.2340\/actadv.v102.2926"},{"key":"30990","doi-asserted-by":"crossref","unstructured":"Melgosa Ramos FJ, Garc\u00eda Ruiz R, Mateu Puchades A, Alfageme Rold\u00e1n F. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: a retrospective bicentric experience. Dermatol Ther 2022; 35: e15558.","DOI":"10.1111\/dth.15558"},{"key":"30991","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.15558","DOI":"10.1111\/dth.15558"},{"key":"30992","doi-asserted-by":"crossref","unstructured":"Burzi L, Repetto F, Ramondetta A, Rozzo G, Licciardello M, Ribero S, Quaglino P, Dapavo P. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? Dermatol Ther 2021; 34: e14930.","DOI":"10.1111\/dth.14930"},{"key":"30993","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/dth.14930","DOI":"10.1111\/dth.14930"},{"key":"30994","doi-asserted-by":"crossref","unstructured":"Ribero S, Ramondetta A, Fabbrocini G, Bettoli V, Potenza C, Chiricozzi A, et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol 2021; 35: e441-e442.","DOI":"10.1111\/jdv.17178"},{"key":"30995","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.17178","DOI":"10.1111\/jdv.17178"},{"key":"30996","doi-asserted-by":"crossref","unstructured":"Revuz JE, Jemec GB. Diagnosing hidradenitis suppurativa. Dermatol Clin 2016; 34: 1-5.","DOI":"10.1016\/j.det.2015.08.009"},{"key":"30997","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.det.2015.08.009","DOI":"10.1016\/j.det.2015.08.009"},{"key":"30998","doi-asserted-by":"crossref","unstructured":"Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017; 177: 1401-1409.","DOI":"10.1111\/bjd.15748"},{"key":"30999","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.15748","DOI":"10.1111\/bjd.15748"},{"key":"31000","doi-asserted-by":"crossref","unstructured":"Cazzaniga S, Pezzolo E, Bettoli V, et al. Characterization of hidradenitis suppurativa phenotypes: a multidimensional latent class analysis of the National Italian Registry IRHIS. J Invest Dermatol 2021; 141: 1236-1242.e1.","DOI":"10.1016\/j.jid.2020.08.032"},{"key":"31001","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jid.2020.08.032","DOI":"10.1016\/j.jid.2020.08.032"},{"key":"31002","doi-asserted-by":"crossref","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"31003","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/5278\/16081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/5278\/16081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T11:55:55Z","timestamp":1681905355000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/5278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":22,"URL":"https:\/\/doi.org\/10.2340\/actadv.v103.5278","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}